Evaluation of the Safety of Calcitonin Gene-Related Peptide Antagonists for Migraine Treatment Among Adults With Raynaud Phenomenon | Zendy

Ilana Breen | Zendy; Caitlin M. Brumfiel | Zendy; Meera H. Patel | Zendy; Richard Butterfield | Zendy; Juliana H. VanderPluym | Zendy; Leroy Griffing | Zendy; Mark R. Pittelkow | Zendy; Aaron R. Mangold | Zendy

Open Access

Evaluation of the Safety of Calcitonin Gene-Related Peptide Antagonists for Migraine Treatment Among Adults With Raynaud Phenomenon

Author(s) -

Ilana Breen,

Caitlin M. Brumfiel,

Meera H. Patel,

Richard Butterfield,

Juliana H. VanderPluym,

Leroy Griffing,

Mark R. Pittelkow,

Aaron R. Mangold

Publication year - 2021

Publication title -

jama network open

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.278

H-Index - 39

ISSN - 2574-3805

DOI - 10.1001/jamanetworkopen.2021.7934

Subject(s) - medicine , calcitonin gene related peptide , migraine , gangrene , cohort , exacerbation , retrospective cohort study , calcitonin , surgery , receptor , neuropeptide

Key Points Question In patients with Raynaud phenomenon, what is the microvascular complication risk of calcitonin gene-related peptide (CGRP) antagonist use? Findings In this cohort study of 169 adults with Raynaud phenomenon, 9 patients had microvascular complications after CGRP antagonist use. Two of the 9 patients had severe adverse events, including digital autonecrosis that required distal amputation. Meaning This study suggests that microvascular complications are uncommon in patients with Raynaud phenomenon who are taking CGRP antagonists; however, the incidence of adverse microvascular events with high morbidity warrants caution in prescribing CGRP antagonists in these patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research